LSBWF
LakeShore Biopharma Co., Ltd
Price Chart
No historical data available
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 2,760 |
Stock Information
Note: Financial values converted from CNY to USD
| Total Debt | $62.44M |
| Cash Equivalents | $36.24M |
| Revenue | $90.46M |
| Net Income | $-14.71M |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Sales | $90.46M |
| Income | $-14.71M |
| Book/sh | $3.55 |
| Employees | 758 |
Financial Ratios
| Quick Ratio | 0.64 |
| Current Ratio | 1.02 |
| Debt/Eq | 72.53 |
Returns & Margins
| ROA | -2.15% |
| ROE | -18.43% |
| Gross Margin | 82.47% |
| Operating Margin | -68.83% |
| Profit Margin | -16.26% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 5.06M |
| Volatility | 1.01 |
Performance History
| YTD | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
đ° Latest News
No news articles available at the moment. Check back later for updates on LSBWF.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $81,676,147 | $81,966,166 | $123,004,302 | $91,910,429 |
| Cost Of Revenue | $107,772,147 | $117,688,301 | $153,360,262 | $117,066,090 |
| Total Revenue | $614,961,584 | $573,418,256 | $687,201,070 | $502,949,894 |
| Operating Revenue | $614,961,584 | $573,418,256 | $687,201,070 | $502,949,894 |
| Expenses | ||||
| Interest Expense | $15,739,410 | $44,344,808 | $30,857,673 | $2,717,433 |
| Total Expenses | $659,412,861 | $841,126,105 | $791,855,417 | $589,411,790 |
| Other Income Expense | $-40,738,637 | $-143,140,821 | $-8,833,581 | $-11,887,950 |
| Other Non Operating Income Expenses | $-5,173,388 | $9,816,210 | $-195,849 | $-2,180,365 |
| Net Non Operating Interest Income Expense | $-15,739,410 | $-44,344,808 | $-30,857,673 | $-2,717,433 |
| Interest Expense Non Operating | $15,739,410 | $44,344,808 | $30,857,673 | $2,717,433 |
| Operating Expense | $551,640,714 | $723,437,804 | $638,495,155 | $472,345,700 |
| Other Operating Expenses | $-5,125,566 | $-20,708,778 | $-26,072,517 | $-23,020,413 |
| Selling And Marketing Expense | $254,742,600 | $280,445,270 | $251,557,826 | $165,716,378 |
| General And Administrative Expense | $135,992,129 | $147,648,044 | $81,440,127 | $107,049,230 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-99,982,451 | $-433,464,871 | $-145,479,105 | $-106,004,401 |
| Net Interest Income | $-15,739,410 | $-44,344,808 | $-30,857,673 | $-2,717,433 |
| Normalized Income | $-64,747,959 | $-287,788,595 | $-139,000,806 | $-98,723,712 |
| Net Income From Continuing And Discontinued Operation | $-99,982,451 | $-433,464,871 | $-145,479,105 | $-106,004,401 |
| Total Operating Income As Reported | $-86,291,884 | $-445,832,502 | $-139,382,351 | $-118,958,663 |
| Net Income Common Stockholders | $-99,982,451 | $-433,464,871 | $-283,470,802 | $-236,666,727 |
| Net Income | $-99,982,451 | $-433,464,871 | $-145,479,105 | $-106,004,401 |
| Net Income Including Noncontrolling Interests | $-99,982,451 | $-433,464,871 | $-145,479,105 | $-106,004,401 |
| Net Income Continuous Operations | $-99,982,451 | $-433,464,871 | $-145,479,105 | $-106,004,401 |
| Pretax Income | $-100,929,324 | $-455,193,478 | $-144,345,601 | $-101,067,279 |
| Special Income Charges | $-36,715,041 | $-157,415,875 | $-8,659,090 | $-9,707,585 |
| Operating Income | $-44,451,277 | $-267,707,849 | $-104,654,347 | $-86,461,896 |
| Depreciation Amortization Depletion Income Statement | $10,555,608 | $6,463,248 | $6,331,847 | $5,998,308 |
| Depreciation And Amortization In Income Statement | $10,555,608 | $6,463,248 | $6,331,847 | $5,998,308 |
| Gross Profit | $507,189,437 | $455,729,955 | $533,840,808 | $385,883,804 |
| Net Income From Tax Loss Carryforward | - | - | $-137,991,697 | $-130,662,326 |
| Net Income Extraordinary | - | - | $-137,991,697 | $-130,662,326 |
| Other | ||||
| Tax Effect Of Unusual Items | $-330,757 | $-7,280,755 | $-2,159,433 | $-2,426,896 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,973,057 | $-215,706,256 | $-68,162,389 | $-57,488,292 |
| Total Unusual Items | $-35,565,249 | $-152,957,031 | $-8,637,732 | $-9,707,585 |
| Total Unusual Items Excluding Goodwill | $-35,565,249 | $-152,957,031 | $-8,637,732 | $-9,707,585 |
| Reconciled Depreciation | $36,651,608 | $42,185,383 | $36,687,807 | $31,153,969 |
| EBITDA (Bullshit earnings) | $-48,538,306 | $-368,663,287 | $-76,800,121 | $-67,195,877 |
| EBIT | $-85,189,914 | $-410,848,670 | $-113,487,928 | $-98,349,846 |
| Diluted NI Availto Com Stockholders | $-99,982,451 | $-433,464,871 | $-283,470,802 | $-236,666,727 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $137,991,697 | $130,662,326 |
| Tax Provision | $-946,873 | $-21,728,607 | $1,133,504 | $4,937,122 |
| Write Off | $8,529,179 | $77,178,879 | $8,655,487 | - |
| Impairment Of Capital Assets | $28,185,862 | $80,236,996 | $0 | $9,476,354 |
| Gain On Sale Of Security | $1,149,792 | $4,458,844 | $21,358 | - |
| Other Taxes | $9,106,850 | $6,789,028 | $6,537,346 | $5,379,934 |
| Research And Development | $146,369,093 | $302,800,992 | $318,700,526 | $211,222,263 |
| Selling General And Administration | $390,734,729 | $428,093,314 | $332,997,953 | $272,765,608 |
| Other Gand A | $48,414,324 | $49,898,015 | $18,688,664 | $45,166,382 |
| Salaries And Wages | $87,577,805 | $97,750,029 | $62,751,463 | $61,882,848 |
| Other Special Charges | - | - | $3,603 | $231,231 |
| Provision For Doubtful Accounts | - | - | $8,655,487 | $5,082,725 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $426,899,975 | $513,960,966 | $650,396,493 | $-779,687,166 |
| Total Assets | $1,367,663,211 | $1,513,027,356 | $1,719,753,611 | $1,441,753,141 |
| Total Non Current Assets | $525,445,211 | $609,859,404 | $683,774,947 | $676,988,748 |
| Other Non Current Assets | $10,295,279 | $34,356,506 | $20,923,703 | $28,228,293 |
| Non Current Deferred Assets | $27,946,500 | $23,634,189 | $1,905,581 | $3,039,084 |
| Non Current Deferred Taxes Assets | $27,946,500 | $23,634,189 | $1,905,581 | $3,039,084 |
| Goodwill And Other Intangible Assets | $72,854,656 | $71,245,336 | $78,056,792 | $80,717,978 |
| Other Intangible Assets | $72,854,656 | $71,245,336 | $78,056,792 | $80,717,978 |
| Current Assets | $842,218,000 | $903,167,952 | $1,035,978,664 | $764,764,393 |
| Other Current Assets | $79,907 | $158,872 | $315,046 | $7,987,914 |
| Restricted Cash | $79,401,410 | $200,000 | $261,766 | $0 |
| Prepaid Assets | $5,270,981 | $5,880,593 | $11,709,976 | $10,648,306 |
| Inventory | $227,591,892 | $203,422,602 | $185,380,952 | $166,505,565 |
| Receivables | $501,790,254 | $447,154,654 | $468,202,865 | $308,555,105 |
| Other Receivables | $104,939 | $1,395,246 | $901,355 | $854,245 |
| Taxes Receivable | $768,500 | $1,598,117 | $4,249,718 | $3,442,733 |
| Accounts Receivable | $500,916,815 | $444,161,291 | $463,051,792 | $308,555,105 |
| Allowance For Doubtful Accounts Receivable | $-30,317,255 | $-29,354,030 | $-24,366,824 | $-13,615,875 |
| Gross Accounts Receivable | $531,234,070 | $473,515,321 | $487,418,616 | $322,170,980 |
| Cash Cash Equivalents And Short Term Investments | $28,083,556 | $246,351,231 | $370,108,059 | $271,067,503 |
| Cash And Cash Equivalents | $28,083,556 | $246,351,231 | $370,108,059 | $271,067,503 |
| Cash Financial | $28,083,556 | $246,351,231 | $370,108,059 | $271,067,503 |
| Receivables Adjustments Allowances | - | - | $-115,743 | $-115,743 |
| Loans Receivable | - | - | - | $0 |
| Debt | ||||
| Net Debt | $385,860,010 | $171,173,281 | $117,419,100 | $94,594,251 |
| Total Debt | $414,400,578 | $424,464,645 | $498,629,596 | $380,589,266 |
| Long Term Debt And Capital Lease Obligation | $23,503,471 | $100,767,373 | $300,139,486 | $264,533,260 |
| Long Term Debt | $23,503,471 | $98,983,780 | $293,790,596 | $253,928,000 |
| Current Debt And Capital Lease Obligation | $390,897,107 | $323,697,272 | $198,490,110 | $116,056,006 |
| Current Debt | $390,440,095 | $318,540,732 | $193,736,563 | $111,733,754 |
| Other Current Borrowings | $37,020,561 | $108,961,932 | $122,961,182 | $394,999 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $867,908,580 | $927,821,054 | $991,300,326 | $2,140,722,329 |
| Total Non Current Liabilities Net Minority Interest | $43,156,058 | $125,595,322 | $332,538,382 | $1,664,808,169 |
| Derivative Product Liabilities | $3,444,842 | $4,548,004 | $8,792,389 | $0 |
| Non Current Deferred Liabilities | $16,207,745 | $20,279,945 | $23,606,507 | $30,053,517 |
| Current Liabilities | $824,752,522 | $802,225,732 | $658,761,944 | $475,914,160 |
| Other Current Liabilities | $99,886,728 | $119,313,398 | $108,795,884 | $94,528,659 |
| Current Deferred Liabilities | $1,455,678 | $2,015,693 | $2,295,701 | $2,295,701 |
| Payables And Accrued Expenses | $332,513,009 | $357,199,369 | $349,180,249 | $263,033,794 |
| Interest Payable | $3,578,336 | $9,909,655 | $6,055,245 | $0 |
| Payables | $127,401,440 | $161,235,923 | $190,532,319 | $145,869,179 |
| Other Payable | $75,049,890 | $90,448,577 | $109,713,235 | $113,886,698 |
| Total Tax Payable | $2,799,771 | $3,012,548 | $379,595 | $1,171,381 |
| Accounts Payable | $49,551,779 | $67,774,798 | $80,439,489 | $30,811,100 |
| Equity | ||||
| Common Stock Equity | $499,754,631 | $585,206,302 | $728,453,285 | $-698,969,188 |
| Total Equity Gross Minority Interest | $499,754,631 | $585,206,302 | $728,453,285 | $-698,969,188 |
| Stockholders Equity | $499,754,631 | $585,206,302 | $728,453,285 | $-698,969,188 |
| Gains Losses Not Affecting Retained Earnings | $-57,271,671 | $-58,179,881 | $-54,412,083 | $83,087,979 |
| Other Equity Adjustments | $-57,271,671 | $-58,179,881 | $-54,412,083 | $83,087,979 |
| Retained Earnings | $-2,407,485,287 | $-2,307,502,836 | $-1,874,037,965 | $-1,590,567,163 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $1,370,221,392 |
| Preferred Stock Equity | - | - | - | $1,370,221,392 |
| Other | ||||
| Ordinary Shares Number | $20,766,531 | $19,022,795 | $9,305,819 | $9,217,499 |
| Share Issued | $20,766,531 | $19,022,795 | $9,305,819 | $9,217,499 |
| Tangible Book Value | $426,899,975 | $513,960,966 | $650,396,493 | $-779,687,166 |
| Invested Capital | $913,698,197 | $1,002,730,814 | $1,215,980,444 | $-333,307,434 |
| Working Capital | $17,465,478 | $100,942,220 | $377,216,720 | $288,850,233 |
| Capital Lease Obligations | $457,012 | $6,940,133 | $11,102,437 | $14,927,512 |
| Total Capitalization | $523,258,102 | $684,190,082 | $1,022,243,881 | $-445,041,188 |
| Additional Paid In Capital | $2,964,482,986 | $2,950,862,914 | $2,656,891,036 | $808,502,018 |
| Capital Stock | $28,603 | $26,105 | $12,297 | $7,978 |
| Common Stock | $28,603 | $26,105 | $12,297 | $7,978 |
| Non Current Deferred Revenue | $16,207,745 | $20,279,945 | $23,606,507 | $30,053,517 |
| Long Term Capital Lease Obligation | $0 | $1,783,593 | $6,348,890 | $10,605,260 |
| Current Deferred Revenue | $1,455,678 | $2,015,693 | $2,295,701 | $2,295,701 |
| Current Capital Lease Obligation | $457,012 | $5,156,540 | $4,753,547 | $4,322,252 |
| Line Of Credit | $353,419,534 | $209,578,800 | $70,775,381 | $111,338,755 |
| Current Accrued Expenses | $205,111,569 | $195,963,446 | $158,647,930 | $117,164,615 |
| Net PPE | $414,348,776 | $480,623,373 | $582,888,871 | $565,003,393 |
| Accumulated Depreciation | $-319,634,840 | $-315,671,428 | $-208,756,137 | $-180,294,493 |
| Gross PPE | $733,983,616 | $796,294,801 | $791,645,008 | $745,297,886 |
| Leases | $2,392,153 | $4,862,781 | $5,597,019 | $4,390,980 |
| Construction In Progress | $287,877,212 | $255,113,837 | $309,948,621 | $318,000,074 |
| Other Properties | $11,574,671 | $17,610,848 | $22,249,868 | $24,957,861 |
| Machinery Furniture Equipment | $432,139,580 | $518,707,335 | $453,849,500 | $397,948,971 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-31,070,837 | $-68,154,238 | $-4,779,446 | $-5,503,029 |
| Finished Goods | $163,931,228 | $153,879,476 | $78,432,041 | $73,285,870 |
| Work In Process | $58,114,028 | $49,083,445 | $61,275,177 | $40,795,744 |
| Raw Materials | $36,617,473 | $68,613,919 | $50,453,180 | $57,926,980 |
| Preferred Stock | - | - | - | $1,370,221,392 |
| Duefrom Related Parties Current | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-138,840,341 | $-339,480,317 | $-239,519,117 | $-472,477,315 |
| Operating Activities | ||||
| Operating Cash Flow | $-120,981,727 | $-295,229,603 | $-182,469,396 | $-173,545,357 |
| Cash Flow From Continuing Operating Activities | $-120,981,727 | $-295,229,603 | $-182,469,396 | $-173,545,357 |
| Operating Gains Losses | $8,627,238 | $-4,445,709 | $-21,358 | $273,982 |
| Investing Activities | ||||
| Capital Expenditure | $-17,858,614 | $-44,250,714 | $-57,049,721 | $-298,931,958 |
| Investing Cash Flow | $-17,006,500 | $-44,250,714 | $-56,981,720 | $-298,923,958 |
| Cash Flow From Continuing Investing Activities | $-17,006,500 | $-44,250,714 | $-56,981,720 | $-298,923,958 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $284,196,000 | $0 | $0 |
| Financing Cash Flow | $-3,580,946 | $205,261,352 | $317,449,926 | $364,558,145 |
| Cash Flow From Continuing Financing Activities | $-3,580,946 | $205,261,352 | $317,449,926 | $364,558,145 |
| Net Common Stock Issuance | $0 | $284,196,000 | $0 | $0 |
| Common Stock Issuance | $0 | $284,196,000 | $0 | $0 |
| Net Other Financing Charges | - | - | $216,572,668 | - |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-338,398,565 | $-416,785,723 | $-146,510,134 | $-49,558,442 |
| Issuance Of Debt | $334,817,619 | $337,851,075 | $247,387,392 | $414,116,587 |
| Interest Paid Supplemental Data | $23,222,931 | $30,131,238 | $27,289,057 | $2,404,357 |
| Income Tax Paid Supplemental Data | $3,365,438 | $0 | $0 | $0 |
| End Cash Position | $107,484,966 | $246,551,231 | $370,369,825 | $271,067,503 |
| Beginning Cash Position | $246,551,231 | $370,369,825 | $271,067,503 | $390,457,084 |
| Effect Of Exchange Rate Changes | $2,502,908 | $10,400,371 | $21,303,512 | $-11,478,411 |
| Changes In Cash | $-141,569,173 | $-134,218,965 | $77,998,810 | $-107,911,170 |
| Net Issuance Payments Of Debt | $-3,580,946 | $-78,934,648 | $100,877,258 | $364,558,145 |
| Net Long Term Debt Issuance | $-3,580,946 | $-78,934,648 | $100,877,258 | $364,558,145 |
| Long Term Debt Payments | $-338,398,565 | $-416,785,723 | $-146,510,134 | $-49,558,442 |
| Long Term Debt Issuance | $334,817,619 | $337,851,075 | $247,387,392 | $414,116,587 |
| Net Intangibles Purchase And Sale | $-5,150,000 | $0 | $-4,291,597 | $-3,617,607 |
| Purchase Of Intangibles | $-5,150,000 | $0 | $-4,291,597 | $-3,617,607 |
| Net PPE Purchase And Sale | $-11,856,500 | $-44,250,714 | $-52,690,123 | $-295,306,351 |
| Sale Of PPE | $852,114 | $0 | $68,001 | $8,000 |
| Purchase Of PPE | $-12,708,614 | $-44,250,714 | $-52,758,124 | $-295,314,351 |
| Change In Working Capital | $-115,380,797 | $-45,789,326 | $-92,746,223 | $-124,936,657 |
| Change In Other Working Capital | $-4,632,215 | $-3,606,570 | $-6,447,010 | $-656,673 |
| Change In Other Current Liabilities | $-5,276,553 | $-5,089,524 | $-4,550,232 | $-3,796,392 |
| Change In Payables And Accrued Expense | $-29,125,938 | $40,555,675 | $92,657,885 | $-21,205,623 |
| Change In Accrued Expense | $-10,902,919 | $53,220,366 | $43,029,496 | $-35,633,487 |
| Change In Payable | $-18,223,019 | $-12,664,691 | $49,628,389 | $14,427,864 |
| Change In Account Payable | $-18,223,019 | $-12,664,691 | $49,628,389 | $14,427,864 |
| Change In Prepaid Assets | $7,468,933 | $-5,289,535 | $8,992,573 | $59,229,802 |
| Change In Inventory | $-24,169,290 | $-86,262,667 | $-18,151,804 | $-89,459,313 |
| Change In Receivables | $-59,645,734 | $13,903,295 | $-165,247,635 | $-69,048,458 |
| Changes In Account Receivables | $-59,645,734 | $13,903,295 | $-165,247,635 | $-99,137,291 |
| Other Non Cash Items | $3,142,729 | $4,778,623 | $4,423,612 | $3,787,628 |
| Stock Based Compensation | $13,557,214 | $9,789,686 | $3,505,001 | $7,764,448 |
| Provisionand Write Offof Assets | $2,890,210 | $4,987,206 | $10,750,949 | $5,084,924 |
| Asset Impairment Charge | $33,824,832 | $148,458,013 | $-723,583 | $4,393,630 |
| Deferred Tax | $-4,312,310 | $-21,728,608 | $1,133,504 | $4,937,120 |
| Deferred Income Tax | $-4,312,310 | $-21,728,608 | $1,133,504 | $4,937,120 |
| Depreciation Amortization Depletion | $36,651,608 | $42,185,383 | $36,687,807 | $31,153,969 |
| Depreciation And Amortization | $36,651,608 | $42,185,383 | $36,687,807 | $31,153,969 |
| Amortization Cash Flow | $6,918,505 | $6,811,456 | $6,952,783 | $6,678,233 |
| Amortization Of Intangibles | $6,918,505 | $6,811,456 | $6,952,783 | $6,678,233 |
| Depreciation | $29,733,103 | $35,373,927 | $29,735,024 | $24,475,736 |
| Gain Loss On Investment Securities | $-1,149,792 | $-4,458,844 | $-21,358 | - |
| Gain Loss On Sale Of PPE | $9,777,030 | $13,135 | $0 | $273,982 |
| Net Income From Continuing Operations | $-99,982,451 | $-433,464,871 | $-145,479,105 | $-106,004,401 |
| Change In Tax Payable | - | - | $0 | $0 |
| Change In Income Tax Payable | - | - | $0 | $0 |
| Taxes Refund Paid | - | - | - | $0 |
Fetched: 2026-02-02